The Trump administration plans to complete its review of the abortion drug mifepristone by March 2027, the Food and Drug Administration said in a court filing, setting a timetable that could lead to new limits on access to the most common method of ending a pregnancy in the United States.
In a filing in Louisiana federal court late on Wednesday, the FDA said it expects to receive the results of a study on the drug’s safety risks in December and will issue a report after interpreting them. Medication abortion is a two-drug regimen, mifepristone followed by misoprostol, used to terminate a pregnancy within the first ten weeks.
The review could lay the groundwork for the agency to revisit the rules that have eased access in recent years, including a 2023 rule allowing the drug to be prescribed remotely and dispensed through the mail. Going further and reconsidering the drug’s original approval in 2000 would be a far more difficult and lengthy process, and most major medical groups, along with the FDA itself at various points since 2000, have said mifepristone is safe and effective when taken as directed, with serious adverse events rare.
The filing was made in a lawsuit brought by the state of Louisiana challenging the mail-order rule. That case has been paused while the FDA review runs, as has a separate, broader lawsuit by Texas and Florida. A third lawsuit by Republican-led states challenging the regulations is pending in Missouri federal court. The office of Louisiana Attorney General Liz Murrill did not immediately respond to a request for comment on the new filing.
The timetable matters because the courts have, in effect, handed the question back to the agency. Rather than judges deciding whether mail-order mifepristone stays or goes, the FDA’s own study, expected in December, and its interpretation of that study, expected by March, will frame what judges are asked to rule on next. An agency report that finds new safety concerns would strengthen the states’ challenges; a report that reaffirms the drug’s record would strengthen the defence of the current rules.
Access to medication abortion has been one of the most contested areas of American health policy since the Supreme Court ended the constitutional right to abortion in 2022 and returned the question to the states. Pills sent by mail across state lines have become central to that fight, used by patients in states with bans and defended by providers and officials in states that protect them.
For now, nothing changes for patients or prescribers: the rules in place remain in place while the review proceeds. What Wednesday’s filing changes is the calendar. The next decisive document in the mifepristone fight is expected in December, and it will come not from a courtroom but from the FDA’s own scientists.
The paused lawsuits are the tell. Louisiana’s challenge to the mail-order rule, the broader Texas and Florida case, and the separate Missouri litigation are all waiting, in different ways, on the same agency process. Judges who might otherwise be ruling on the legality of mailing abortion pills will instead be handed an FDA study and asked to defer to it, or not. That gives the December results an importance beyond their scientific content: they will set the terms of every courtroom argument that follows, in a fight where the science, the regulations and the politics have never been separable.
Related reading: Kennedy Launches Agency-Wide Push to Document Reported Vaccine Injuries · Half a Century of Nurses' Health Studies Shows Prevention Works Across Diseases · UK Review Warns ADHD and Autism Diagnoses Risk Blurring Normal Variation
